Search clinical trials for: HER2/neu positive breast cancer

Total 96134 results

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Breast Neoplasms

China
Memorial Sloan Kettering Cancer Center

Recruiting

Exercise Treatment With Standard Therapy for Metastatic Breast Cancer

Hormone Receptor Positive Metastatic Breast Cancer

United States
Centre Oscar Lambret

Recruiting

Feasibility of a New Technology for Isolating Circulating Tumour Cells (CTC-SMMiL-E)

Ovarian Cancer | Hormone-resistant Prostate Cancer | Circulating Tumor Cell | HER2-positive Metastatic Breast Cancer

France
Seagen Inc.

Recruiting

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

HER2-positive Breast Cancer

United States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Fudan University

Recruiting

Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer (CLOVER)

Breast Cancer

China
Yonsei University

Recruiting

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Metastatic Breast Cancer | HER2-positive Breast Cancer | Postmenopausal

Korea, Republic of
Peking Union Medical College Hospital

Not yet recruiting

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (Pyrotinib)

Breast Diseases | Metastatic Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female | Hormone Receptor Positive Tumor
Ruijin Hospital

Recruiting

Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer (NeoPATH)

Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer

China
St Vincent's Hospital

Recruiting

A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. (WinPro)

Hormone Receptor Positive Tumor | Early-stage Breast Cancer

Australia
University of Chicago

Recruiting

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III

Nigeria
ETOP IBCSG Partners Foundation
Pfizer

Recruiting

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

Breast Cancer Recurrent

Switzerland, Italy, France, Spain, Hungary, Austria
National Cancer Institute (NCI)

Recruiting

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage III HPV-Mediated (p16-Positive)...

United States
British Columbia Cancer Agency
Genomic Health®, Inc.

Not yet recruiting

Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers (ER)

Breast Cancer
Dana-Farber Cancer Institute
Kazia Therapeutics Limited

Recruiting

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Breast Cancer

United States
Gangnam Severance Hospital
Samsung Medical Center; Asan Medical Center; Severance Hospital

Recruiting

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (CLEAR)

Breast Cancer | Surgery | Recurrent Breast Cancer | Estrogen Receptor Positive Tumor | Stereotactic Body Radiotherapy | Her2-negative Tumor

Korea, Republic of
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (VISTA)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Pancreatic Adenocarcinoma | Lung Cancer | Solid Tumor | Bladder Cancer | Head and Neck Squamous Cell Carcinoma | Cancer of the Salivary Gland

United States
Hebei Medical University Fourth Hospital
OrigiMed

Recruiting

Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer

Prospective | Observational

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Elevated CA15-3 or CEA or CA27-29

United States, Puerto Rico, Guam
InSightec

Recruiting

Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases (BBBD)

Breast Cancer | Brain Metastases

Canada
City of Hope Medical Center
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

Breast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Leptomeninges

United States
Shandong Cancer Hospital and Institute

Not yet recruiting

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

HER2-positive Breast Cancer
Henrik Lindman
Roche Pharma AG; Swedish Breast Cancer Group; Swedish Cancer Society; Affibody

Recruiting

A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer (Affibody-3)

HER2-positive Breast Cancer

Sweden
Yonsei University

Recruiting

Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer

Triple Negative Breast Cancer | Metastatic Breast Cancer With HER2 Positive

Korea, Republic of
Centre Leon Berard
Amgen

Recruiting

Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (BREASTIMMU02)

HER2-positive Breast Cancer | Operable Breast Cancer

France
OBI Pharma, Inc

Recruiting

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Triple Negative Breast Cancer

China, Taiwan, United States, Korea, Republic of, Australia, Brazil, Hong Kong, Mexico, Russian Federation, South Africa, Ukraine, Peru, Poland
Sun Yat-sen University

Recruiting

A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients (SMART)

Breast Cancer

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Minimal Residual Disease | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
University Hospital, Basel, Switzerland
ETOP IBCSG Partners Foundation; Austrian Breast Cancer Study Group

Recruiting

Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) (TAXIS)

Node-positive Breast Cancer

Greece, Switzerland, Hungary, Austria, Germany, Italy, Lithuania, Argentina, Croatia
National Cancer Center, Korea

Recruiting

Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer (NeoChAI)

Breast Cancer | Invasive Breast Cancer

Korea, Republic of
Yonsei University

Not yet recruiting

Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)

Metastatic Breast Cancer

Korea, Republic of
Canadian Cancer Trials Group
Alliance for Clinical Trials in Oncology; NRG Oncology; Eastern Cooperative Oncology... and other collaborators

Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (TAILOR RT)

Breast Cancer

United States, Canada
Sidney Kimmel Comprehensive Cancer Center at Johns...
Safeway Foundation

Recruiting

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

Breast Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

Cardiotoxicity | Recurrent Breast Carcinoma | HER2/Neu Positive | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7

United States, Korea, Republic of, Puerto Rico, Saudi Arabia
Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast Cancer

United States, Japan
University of Alabama at Birmingham
Tesaro, Inc.; Susan G. Komen Breast Cancer Foundation; Translational Breast Cancer... and other collaborators

Recruiting

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Metastatic Breast Cancer | HER2 Positive Breast Carcinoma

United States
German Breast Group
Pfizer; AMS Advanced Medical Services GmbH

Recruiting

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA)

Metastatic Breast Cancer

Germany
Chinese Anti-Cancer Association
Zhejiang Cancer Hospital; Fudan University; Cancer Institute and Hospital, Chinese... and other collaborators

Recruiting

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Breast Cancer Female

China
Massachusetts General Hospital
Novartis

Recruiting

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer (LEADER)

Breast Cancer

United States
Tao OUYANG

Recruiting

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Primary Breast Cancer

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Mantle Cell Lymphoma | CD20 Positive

United States
Qamar Khan

Recruiting

Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer (HERMET)

HER2-positive Breast Cancer

United States
University of Wisconsin, Madison
National Center for Advancing Translational Sciences (NCATS)

Recruiting

FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

Invasive Breast Cancer

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Columbia University

Recruiting

Comparison of the Breast Tumor Microenvironment

Triple Negative Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001)

Non-Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Any Solid Tumor

United States, Japan, Taiwan, Australia, Korea, Republic of, Israel, Spain, Switzerland, Singapore, France, Canada, Italy, Germany, United Kingdom, Hong Kong, Denmark
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca; Cancer Research UK

Recruiting

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer (PARTNER)

Breast Cancer

United Kingdom
Northwestern University
National Cancer Institute (NCI); BHR Pharma, LLC

Recruiting

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Estrogen Receptor Positive | Ductal Breast Carcinoma In Situ

United States
Centre Jean Perrin

Recruiting

Adapted Physical Activity for Breast Cancer HER2 Positive Patient (APACAN2)

HER2 Positive Breast Cancer

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Invasive Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | HER2 Positive Breast Carcinoma | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC... and other conditions

United States

Search clinical trials for: HER2/neu positive breast cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations